myirislogo
21 October, 2019 11:09 IST
My Last 5 Scrips
Company BSE Price (Rs) % Chg
Tata Motors 136.70 1.05
State Bank O 269.65 1.58
Tata Stl 359.90 1.19
Tata Power 60.05 0.42
Reliance 1415.30 1.37
Clear All Clear Last
   
NSE Live
Nifty Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Nse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
BSE Live
BSE30 Live Prices
Top Gainers/Losers
Top 10 Turnover
No Delivery Stocks
Advances / Declines new
Index Weightage new
Exchange Holidays new
Bse Sectors new
Contribution To Index new
Bonus new
Rights new
Delisted-Shares new
Split of Value new
Market Pulse
Leaders
Laggards
FII Activity
Mutual Fund Activity
Meetings
Results Watch
Results Calendar
Results Announced
Watch
Sector Watch
Economy Watch
Company
Snapshots
Quotes
Charts
Financials
Recent News
Broker Research
Meetings
Research Tutorial
Research
Research Reports
Snapshot-Astrazeneca Pharma India Limited
Astrazeneca Pharma India Limited
Sector:Pharmaceuticals Pharmaceuticals - Formulations
BSE:506820NSE:ASTRAZENBloomberg:ASTR@INReuters:ASTR.BO
Market Lot: 1Face Value: 2ISIN Demat: INE203A01020
QuotesSnapshotChartsFinancialsResearchRecent News
Peer GroupAGM/AMMF HoldingDiscussion ForumBSE/NSE NoticesBSE/NSE Deals

 
 
Recent Developments
22-JUN-18 AstraZeneca Pharma India (AZPIL) announced that it has received Import & Market permission for Durvalumab (ImfinziTM) in India by the Drug Controller General of India (DCGI). The receipt of this permission paves way for the launch of durvalumab (ImfinziTM) in India, subject to the receipt of further related statutory approvals and licenses. 16-JUN-17 AstraZeneca Pharma India has received Import and Market permission in Form 45 (Mark...   More..
Business Profile Future Plans
One To One
Recent news
Latest News
AstraZeneca Pharma gets Indian drug regulators' nod for Symbicort Turbuhaler  -IRIS 16-Jun-17
Previous

 


Brief Financials (in Rs. Mn.) 
Period ending (months)31-Mar-2016(12)31-Mar-2015 (12)31-Mar-2014 (12)
Net sales 5264.604690.494737.48
Other Income68.2458.4892.08
Total Income5332.844748.974829.56
Cost of goods sold5473.665284.764869.43
OPBDIT-140.82-535.79-39.87
PAT52.59-208.40-5.09
Gross Block---
Equity capital50.0050.0050.00
EPS (Rs.)--8.34-0.20
DPS (Rs.)---
BV (Rs.)---
P/E range (x)-NANA
Debt / Equity (x)---
Operating margin (% of OI)-2.6-11.3-0.8
Net margin (% of OI) 1.0-4.4-0.1
Detailed Financials
Income 
Statement
Balance Sheet Latest 
Quarterly/Halfyearly
Ratio Analysis Share Statistics
Price Charts
Scrip Information



Registered Office
ADDRESS
Avishkar
Off Bellary Road
Hebbal
Bangalore
Karnataka-560 024
PHONE
(080) 2362 2021-27
FAX
(080) 2362 2015
 
Board of Directors
NSE/BSE Announcements


Home | Shares | F&O | Mutual Funds | Loans | Insurance | News Centre
Wealth Tracker | Tax Corner | NRI Centre | Search in myiris | Advertise
All rights reserved. IRIS Business Services Limited
Disclaimer